Moleculin Days Payables Outstanding from 2010 to 2024

MBRX Stock  USD 2.62  0.03  1.13%   
Moleculin Biotech Days Payables Outstanding yearly trend continues to be fairly stable with very little volatility. Days Payables Outstanding is likely to outpace its year average in 2024. During the period from 2010 to 2024, Moleculin Biotech Days Payables Outstanding regression line of annual values had r-squared of  0.72 and arithmetic mean of  13,645. View All Fundamentals
 
Days Payables Outstanding  
First Reported
2010-12-31
Previous Quarter
7.2 K
Current Value
7.6 K
Quarterly Volatility
9.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 120.7 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Days Payables Outstanding Growth Pattern

Below is the plot of the Days Payables Outstanding of Moleculin Biotech over the last few years. It is Moleculin Biotech's Days Payables Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Days Payables Outstanding10 Years Trend
Slightly volatile
   Days Payables Outstanding   
       Timeline  

Moleculin Days Payables Outstanding Regression Statistics

Arithmetic Mean13,645
Geometric Mean9,421
Coefficient Of Variation72.02
Mean Deviation9,323
Median7,630
Standard Deviation9,827
Sample Variance96.6M
Range22.2K
R-Value(0.85)
Mean Square Error29.5M
R-Squared0.72
Significance0.000069
Slope(1,860)
Total Sum of Squares1.4B

Moleculin Days Payables Outstanding History

2024 7630.04
2023 7179.29
2022 3444.48
2021 1914.85
2020 1445.91
2019 4247.81

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Days Payables Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Payables Outstanding7.2 K7.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.